zilovertamab,ibrutinib
oncternal therapeutics,janssen,abbvie,merck
['zilovertamab', 'ibru', 'oncternal', '$onct']
$onct [15s. delayed]: issued press release on june 10, 09:00:00: oncternal therapeutics presents rationale and plans for its registrational phase 3 study evaluating zilovertamab in combination with ibrutinib at the eha 2022 congress 
Flash Alert is a low-latency financial news service which sources SEC, press releases, credible news sources to get your news about stocks in near real-time